Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry
Introduction
Patients with myelodysplastic syndromes (MDS) suffer from peripheral blood cytopenias as a result of bone marrow failure. Besides medullary blast count and karyotype, transfusion dependency has been identified as an important prognostic factor [1], [2] and has therefore been integrated into the WHO-classification based prognostic scoring system (WPSS) [3].
Despite new treatment options, many MDS patients rely on red blood cell transfusions. Chronic transfusion therapy causes iron overload. Recently, a large retrospective analysis showed that iron overload, defined as a serum ferritin >1000 ng/ml, was a significant prognostic factor for OS and leukemia-free survival in MDS [1]. On multivariate analysis, the influence of iron overload was independent of transfusion requirement.
If iron overload shortens the survival of patients with MDS, iron chelation (IC) should do the opposite. This view is supported by a partly retrospective and partly prospective observational study by Rose et al. [4] showing that patients with an IPSS low or intermediate-1 risk profile who received iron chelation therapy lived longer than patients who did not. However, there are as yet no results available from randomized clinical trials to confirm such a survival benefit. We performed a retrospective matched-pair analysis drawing on the data base of the Düsseldorf MDS registry.
Section snippets
Methods
At the time of patient selection the Düsseldorf MDS registry included 3552 patients, diagnosed between 1975 and 2008. For matched-pair analysis [5] we identified 94 polytransfused MDS patients who had been receiving long-term chelation therapy. The registry was then searched for matching partners who received supportive care, including growth factors, but neither iron chelators nor disease-modifying drugs. The following characteristics were used for matching: age at diagnosis (±5 years),
Results
Patient characteristics are shown in Table 1a, Table 1b. All 188 patients showed iron overload, defined as a serum ferritin ≥1000 ng/ml, or a history of multiple transfusions and a serum ferritin ≥500 ng/ml. All ferritin levels were measured at the time of referral to our center, which was usually early after diagnosis. The proportion of heavily transfusion-dependent patients was largest among patients with del(5q), RCMD, and refractory anemia with excess blasts (RAEB-I and -II). At least 50% of
Discussion
In the field of thalassemia, it is well established that transfusional iron overload limits life expectancy due to toxic effects on heart, liver and other organs. In patients with MDS, the situation is more difficult to understand. Chronic transfusion therapy is clearly associated with a decreased likelihood of overall survival and leukemia-free survival [1], [2]. There is a dose-dependent effect of transfusion requirement, and a similar dose-dependent effect of serum ferritin levels, on
Funding source
This work was supported by Novartis Pharma AG. The sponsor was not involved in collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. Part of the data have been presented at ASH 2009, Abstract 1747.
Conflict of interest
U.G. and N.G. received speakers honorary and research support from Novartis Pharma AG. F.F. and A.K. received speakers honorary from Novartis Pharma AG.
Acknowledgments
Contributions. U.G. and N.G. made the conception and design of the study. J.N., U.G. and N.G. were responsible for analysis and interpretation of the data, and J.N. wrote the manuscript. F.F., A.K., N.K. and C.S. acquired the data, U.G. and N.G. revised the article critically and R.H. revised the article critically and gave the final approval.
References (8)
- et al.
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients. A multicenter study by the GFM
Leuk Res
(2010) - et al.
Improved survival in patient with myelodysplastic syndrome receiving iron chelation therapy
Clin Leuk
(2008) Iron chelation therapy in MDS: does it improve survival
Leuk Res
(2010)- et al.
Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome
Blood
(2008)
Cited by (110)
Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae
2021, Critical Reviews in Oncology/HematologyIron overload and its impact on outcome of patients with hematological diseases
2020, Molecular Aspects of MedicineToo much iron: A masked foe for leukemias
2020, Blood ReviewsHematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions
2019, Critical Reviews in Oncology/HematologyCitation Excerpt :However, the organs of patients with MDS are also older, possibly making them more susceptible to a deleterious effect of iron. A number of studies indicate that ICT in patients with MDS may have beneficial effects on organ function and OS; however, these data are from non-randomized studies and the results are therefore debated, pending full results from the prospective, randomized controlled trial of ICT with deferasirox (DFX) in MDS (NCT00940602) (Abraham et al., 2017; Angelucci et al., 2018; Chee et al., 2008; ClinicalTrials.gov, 2016; Gattermann et al., 2010b; Guariglia et al., 2011; Hoeks et al., 2017; Leitch, 2007; Leitch et al., 2008, 2017b; Lyons et al., 2017; Mainous et al., 2014; Neukirchen et al., 2012; Remacha et al., 2015; Rose et al., 2010; Steensma, 2009; Tefferi and Stone, 2009; Wong and Leitch, 2018; Zeidan et al., 2015). A consistent, and initially surprising observation in clinical studies of ICT in MDS is hematologic improvement (HI) in a significant minority of patients, including a reduction in RBC transfusion requirements and even transfusion independence (Angelucci et al., 2014; Gattermann et al., 2012; Nolte et al., 2013).